Veru Inc. (VERU) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Veru Inc. (VERU) closed at USD 2.44 on 2026-10-15, a change of -30.3 % over the past year, with a market capitalization of USD 39.22M.

Veru Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Veru Inc. key figures

Previous close

USD 2.44 (2026-10-15)

1-year change

-30.3 %

Market cap

USD 39.22M

Enterprise value

USD 16.16M

P/E ratio (trailing)

-3.77

P/E ratio (forward)

-2.30

EPS (trailing)

-0.61

EPS (forward)

-1.00

PEG ratio

3.60

Price to book

1.38

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.90

Employees

20

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Veru Inc.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Veru Inc. and compare it with other stocks.